{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:56:05Z","timestamp":1787590565324,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"ACTION Study Group"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40256-024-00683-z","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T14:03:39Z","timestamp":1729519419000},"page":"249-258","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Levosimendan in Patients with Cardiogenic Shock Refractory to Dobutamine Weaning"],"prefix":"10.1007","volume":"25","author":[{"given":"Michel","family":"Zeitouni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Dorvillius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Procopi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Beaupr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perrine","family":"Devos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Barth\u00e9l\u00e9my","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Rouanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Chommeloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Hekimian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Kerneis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne","family":"Silvain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0824-6809","authenticated-orcid":false,"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the ACTION Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"683_CR1","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1056\/NEJMoa1808788","volume":"379","author":"H Thiele","year":"2018","unstructured":"Thiele H, Akin I, Sandri M, et al. One-year outcomes after PCI strategies in cardiogenic shock. N Engl J Med. 2018;379:1699\u2013710. https:\/\/doi.org\/10.1056\/NEJMoa1808788.","journal-title":"N Engl J Med"},{"key":"683_CR2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ahj.2015.11.006","volume":"172","author":"H Thiele","year":"2016","unstructured":"Thiele H, Desch S, Piek JJ, et al. Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: design and rationale of CULPRIT-SHOCK trial. Am Heart J. 2016;172:160\u20139. https:\/\/doi.org\/10.1016\/j.ahj.2015.11.006.","journal-title":"Am Heart J"},{"key":"683_CR3","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jchf.2020.09.005","volume":"8","author":"BN Tehrani","year":"2020","unstructured":"Tehrani BN, Truesdell AG, Psotka MA, et al. A standardized and comprehensive approach to the management of cardiogenic shock. JACC Heart Fail. 2020;8:879\u201391. https:\/\/doi.org\/10.1016\/j.jchf.2020.09.005.","journal-title":"JACC Heart Fail."},{"key":"683_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijcard.2011.07.022","volume":"159","author":"Z Papp","year":"2012","unstructured":"Papp Z, \u00c9des I, Fruhwald S, et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012;159:82\u20137. https:\/\/doi.org\/10.1016\/j.ijcard.2011.07.022.","journal-title":"Int J Cardiol"},{"key":"683_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jchf.2012.12.004","volume":"1","author":"M Packer","year":"2013","unstructured":"Packer M, Colucci W, Fisher L, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013;1:103\u201311. https:\/\/doi.org\/10.1016\/j.jchf.2012.12.004.","journal-title":"JACC Heart Fail."},{"key":"683_CR6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/00000542-200603000-00024","volume":"104","author":"WG Toller","year":"2006","unstructured":"Toller WG, Stranz C, Warltier DC. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology. 2006;104:556\u201369. https:\/\/doi.org\/10.1097\/00000542-200603000-00024.","journal-title":"Anesthesiology"},{"key":"683_CR7","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/s0735-1097(00)00961-x","volume":"36","author":"MS Nieminen","year":"2000","unstructured":"Nieminen MS, Akkila J, Hasenfuss G, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1903\u201312. https:\/\/doi.org\/10.1016\/s0735-1097(00)00961-x.","journal-title":"J Am Coll Cardiol"},{"key":"683_CR8","doi-asserted-by":"publisher","first-page":"9704","DOI":"10.1038\/srep09704","volume":"5","author":"M Adam","year":"2015","unstructured":"Adam M, Meyer S, Knors H, et al. Levosimendan displays anti-inflammatory effects and decreases MPO bioavailability in patients with severe heart failure. Sci Rep. 2015;5:9704. https:\/\/doi.org\/10.1038\/srep09704.","journal-title":"Sci Rep"},{"key":"683_CR9","unstructured":"Masson E. Effects of Levosimendan Versus Dobutamine on Inflammatory and Apoptotic Pathways in Acutely Decompensated Chronic Heart Failure. EM-Consulte. Available at: https:\/\/www.em-consulte.com\/article\/412930\/references\/effects-of-levosimendan-versus-dobutamine-on-infla. Accessed 18 Sep 2023"},{"key":"683_CR10","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/ejhf.1145","volume":"20","author":"J Com\u00edn-Colet","year":"2018","unstructured":"Com\u00edn-Colet J, Manito N, Segovia-Cubero J, et al. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. Eur J Heart Fail. 2018;20:1128\u201336. https:\/\/doi.org\/10.1002\/ejhf.1145.","journal-title":"Eur J Heart Fail"},{"key":"683_CR11","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","volume":"297","author":"A Mebazaa","year":"2007","unstructured":"Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA. 2007;297:1883\u201391. https:\/\/doi.org\/10.1001\/jama.297.17.1883.","journal-title":"JAMA"},{"key":"683_CR12","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1097\/CCM.0b013e318232962a","volume":"40","author":"G Landoni","year":"2012","unstructured":"Landoni G, Biondi-Zoccai G, Greco M, et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med. 2012;40:634\u201346. https:\/\/doi.org\/10.1097\/CCM.0b013e318232962a.","journal-title":"Crit Care Med"},{"key":"683_CR13","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/bja\/aev284","volume":"115","author":"A Belletti","year":"2015","unstructured":"Belletti A, Castro ML, Silvetti S, et al. The effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials. Br J Anaesth. 2015;115:656\u201375. https:\/\/doi.org\/10.1093\/bja\/aev284.","journal-title":"Br J Anaesth"},{"key":"683_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2024.07.059","author":"D Sulman","year":"2024","unstructured":"Sulman D, Beaupr\u00e9 F, Devos P, et al. Ten-year trends in characteristics, management and outcomes of patients admitted with cardiogenic shock in the ACTION-SHOCK cohort. Arch Cardiovasc Dis. 2024. https:\/\/doi.org\/10.1016\/j.acvd.2024.07.059.","journal-title":"Arch Cardiovasc Dis"},{"key":"683_CR15","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jacc.2022.01.018","volume":"79","author":"SS Naidu","year":"2022","unstructured":"Naidu SS, Baran DA, Jentzer JC, et al. SCAI SHOCK Stage classification expert consensus update: a review and incorporation of validation studies: this statement was endorsed by the American College of Cardiology (ACC), American College of Emergency Physicians (ACEP), American Heart Association (AHA), European Society of Cardiology (ESC) Association for Acute Cardiovascular Care (ACVC), International Society for Heart and Lung Transplantation (ISHLT), Society of Critical Care Medicine (SCCM), and Society of Thoracic Surgeons (STS) in December 2021. J Am Coll Cardiol. 2022;79:933\u201346. https:\/\/doi.org\/10.1016\/j.jacc.2022.01.018.","journal-title":"J Am Coll Cardiol"},{"key":"683_CR16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000590","volume":"3","author":"D Kolte","year":"2014","unstructured":"Kolte D, Khera S, Aronow WS, et al. Trends in incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction in the United States. J Am Heart Assoc. 2014;3: e000590. https:\/\/doi.org\/10.1161\/JAHA.113.000590.","journal-title":"J Am Heart Assoc"},{"key":"683_CR17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s13054-016-1387-1","volume":"20","author":"T Tarvasm\u00e4ki","year":"2016","unstructured":"Tarvasm\u00e4ki T, Lassus J, Varpula M, et al. Current real-life use of vasopressors and inotropes in cardiogenic shock\u2014adrenaline use is associated with excess organ injury and mortality. Crit Care. 2016;20:208. https:\/\/doi.org\/10.1186\/s13054-016-1387-1.","journal-title":"Crit Care"},{"key":"683_CR18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jacc.2020.11.025","volume":"77","author":"O Barth\u00e9l\u00e9my","year":"2021","unstructured":"Barth\u00e9l\u00e9my O, Rouanet S, Brugier D, et al. Predictive value of the residual SYNTAX score in patients with cardiogenic shock. J Am Coll Cardiol. 2021;77:144\u201355. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.025.","journal-title":"J Am Coll Cardiol"},{"key":"683_CR19","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.021150","volume":"10","author":"B Schrage","year":"2021","unstructured":"Schrage B, Zeymer U, Montalescot G, et al. Impact of center volume on outcomes in myocardial infarction complicated by cardiogenic shock: a CULPRIT-SHOCK substudy. J Am Heart Assoc. 2021;10: e021150. https:\/\/doi.org\/10.1161\/JAHA.120.021150.","journal-title":"J Am Heart Assoc"},{"key":"683_CR20","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","volume":"360","author":"F Follath","year":"2002","unstructured":"Follath F, Cleland JGF, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. The Lancet. 2002;360:196\u2013202. https:\/\/doi.org\/10.1016\/S0140-6736(02)09455-2.","journal-title":"The Lancet"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00683-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-024-00683-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00683-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T07:28:20Z","timestamp":1739172500000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-024-00683-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["683"],"URL":"https:\/\/doi.org\/10.1007\/s40256-024-00683-z","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]},"assertion":[{"value":"11 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by the ACTION Study Group.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Michel Zeitouni has received research grants and honorarium from Bayer, BMS Pfizer, la F\u00e9d\u00e9ration Fran\u00e7aise de Cardiologie, Servier, AstraZeneca, NovoNordisk, and Abbott. Johanne Silvain has received research grants and honorarium from AstraZeneca, Bayer HealthCare SAS, Abbott Medical France SAS, Biotronik, Boehringer Ingelheim France, CSL Behring SA, Gilead Science, and Sanofi-Aventis France; and is a stockholder of Pharmaseeds, Terumo France SAS, and Zoll. Gilles Montalescot has received research grants and honorarium from Abbott, Amgen, AstraZeneca, Ascendia, Bayer, BMS, Boehringer-Ingelheim, BostonScientific, Celecor, CSL Behring, Idorsia, Lilly, Novartis, Novo, Opalia, Pfizer, Quantum Genomics, Sanofi, and Terumo; and is an Editorial Board member of the American Journal of Cardiovascular Drugs but was not involved in the selection of peer reviewers for this manuscript nor any of the subsequent editorial decisions. Elodie Dorvillius, David Sulman, Niki Procopi, Frederic Beaupr\u00e9, Perrine Devos, Olivier Barth\u00e9l\u00e9my, St\u00e9phanie Rouanet, Arnaud Ferrante, Juliette Chommoeloux, Guillaume Hekimian, and Mathieu Kerneis have no conflicts of interest to declare that may be relevant to the contents of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"MZ, JS, GM: Supervision, validation, visualization, writing, reviewing and editing, funding, methodology. ED, DS, NP, FB, PD, OB, AF, JC, GH, MK: Conceptualization, data curation, investigation, writing, reviewing, editing. SR: Statistician, methodology, project administration software, validation","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}},{"value":"The datasets analyzed during the current study are available from the corresponding author, Michel Zeitouni, upon reasonable request. Access will be granted following appropriate review and approval.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"This analysis was undertaken in participants from the ACTION-SHOCK registry that was approved by the Ethics Committee of Sorbonne Universit\u00e9, Paris, France (CER-2022-047).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"An information letter was sent to all patients matching the selection criteria stating their right to decline participation. In the absence of refusal, the patient was included in the study.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}